NeuShen Therapeutics has announced the successful closure of a $20 million Series pre-A financing round led by Lapam Capital. The proceeds will be used to advance the company’s central nervous system (CNS) drug research and development platform, as well as to support the development of new drugs targeting CNS disorders.
Company Overview and Research Platforms
NeuShen Therapeutics is a biotech company operating out of Shanghai, China, and Boston, Massachusetts, in the US. The company is focused on innovative drug research and development to address CNS disorders. NeuShen employs dual research platforms, including AAV-based gene therapy and small molecule discovery, to drive its pipeline forward.
Future Outlook
With the support of this financing round, NeuShen Therapeutics aims to strengthen its CNS drug development capabilities and accelerate the progress of its innovative therapies. The company’s dual research platforms position it well to address the significant unmet needs in the CNS therapeutic area.-Fineline Info & Tech
